Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John B Buse

Showing results (151-160 of 457) with videos related to

Pageof 46
Sort By:
Diabetes Care|February 24, 2021
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 DiabetesKlara R Klein, Jennifer L R Freeman, Imogene Dunn, et al.
Diabetes Care|March 25, 2010
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agentsJohn B Buse, Giorgio Sesti, Wolfgang E Schmidt, et al.
ACS Nano|January 5, 2017
H<sub>2</sub>O<sub>2</sub>-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin DeliveryXiuli Hu, Jicheng Yu, Chenggen Qian, et al.
Nano Letters|January 13, 2017
Hypoxia and H<sub>2</sub>O<sub>2</sub> Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin DeliveryJicheng Yu, Chenggen Qian, Yuqi Zhang, et al.
JAMA|March 9, 2016
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical TrialSteven E Nissen, Kathy E Wolski, Lisa Prcela, et al.
Lancet (London, England)|June 29, 2023
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trialVanita R Aroda, Jens Aberle, Lars Bardtrum, et al.
Diabetes Care|June 19, 2023
Impact of Continuous Glucose Monitoring Initiation on Emergency Health Services UtilizationJoshua M Weinstein, Ben Urick, Shweta Pathak, et al.
Diabetologia|December 20, 2019
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)John B Buse, Deborah J Wexler, Apostolos Tsapas, et al.
The Journal of Pediatrics|February 19, 2013
Low-density lipoprotein cholesterol versus particle number in middle school childrenMichele Mietus-Snyder, Kimberly L Drews, James D Otvos, et al.
BMJ Open Diabetes Research & Care|November 25, 2021
Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTEKlara R Klein, Edward Franek, Steven Marso, et al.
Pageof 46

Showing results (151-160 of 457) with videos related to

Sort By:
Pageof 46
Diabetes Care|February 24, 2021
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 DiabetesKlara R Klein, Jennifer L R Freeman, Imogene Dunn, et al.
Diabetes Care|March 25, 2010
Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agentsJohn B Buse, Giorgio Sesti, Wolfgang E Schmidt, et al.
ACS Nano|January 5, 2017
H<sub>2</sub>O<sub>2</sub>-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin DeliveryXiuli Hu, Jicheng Yu, Chenggen Qian, et al.
Nano Letters|January 13, 2017
Hypoxia and H<sub>2</sub>O<sub>2</sub> Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin DeliveryJicheng Yu, Chenggen Qian, Yuqi Zhang, et al.
JAMA|March 9, 2016
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical TrialSteven E Nissen, Kathy E Wolski, Lisa Prcela, et al.
Lancet (London, England)|June 29, 2023
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trialVanita R Aroda, Jens Aberle, Lars Bardtrum, et al.
Diabetes Care|June 19, 2023
Impact of Continuous Glucose Monitoring Initiation on Emergency Health Services UtilizationJoshua M Weinstein, Ben Urick, Shweta Pathak, et al.
Diabetologia|December 20, 2019
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)John B Buse, Deborah J Wexler, Apostolos Tsapas, et al.
The Journal of Pediatrics|February 19, 2013
Low-density lipoprotein cholesterol versus particle number in middle school childrenMichele Mietus-Snyder, Kimberly L Drews, James D Otvos, et al.
BMJ Open Diabetes Research & Care|November 25, 2021
Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTEKlara R Klein, Edward Franek, Steven Marso, et al.
Pageof 46